Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Aug;22(9):1215-23.
doi: 10.1177/1352458515614092. Epub 2015 Oct 29.

Alemtuzumab for Multiple Sclerosis: Long Term Follow-Up in a Multi-Centre Cohort

Affiliations
Multicenter Study

Alemtuzumab for Multiple Sclerosis: Long Term Follow-Up in a Multi-Centre Cohort

M D Willis et al. Mult Scler. .

Abstract

Background: Alemtuzumab has recently been approved for treatment of relapsing MS, but concerns remain about its use since long-term studies of adverse events remain limited. Furthermore, a clear understanding of its application and durability of effect in clinical practice has yet to evolve.

Objectives: To investigate long-term efficacy and safety outcomes in a multicentre cohort of patients treated with alemtuzumab.

Methods: Patients treated from 2000 and followed-up at three regional centres were identified. Baseline and prospective data were obtained and validated by clinical record review.

Results: One hundred patients were identified with a mean follow-up of 6.1 years (range 1-13). Forty patients were retreated with at least one further treatment cycle. Annualized relapse rates fell from 2.1 to 0.2 (p<0.0001) post-treatment and were sustained for up to eight years of follow-up. Mean change in EDSS score was +0.14. Forty-seven patients developed secondary autoimmunity.

Conclusion: Observed reduction in relapse rates reflected those reported in clinical trials, but we were unable to corroborate previous observations of disability reversal. 40% of patients required additional treatment cycles. Autoimmune adverse events were common, occurring at a higher rate than previously reported, but were largely predictable, and could be managed effectively within a rigorous monitoring regime.

Keywords: Multiple sclerosis; alemtuzumab; autoimmunity.

Similar articles

See all similar articles

Cited by 22 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback